Gibbs Wealth Management Purchases 15,937 Shares of CVS Health Corporation $CVS

Gibbs Wealth Management boosted its position in shares of CVS Health Corporation (NYSE:CVS) by 110.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 30,430 shares of the pharmacy operator’s stock after acquiring an additional 15,937 shares during the quarter. Gibbs Wealth Management’s holdings in CVS Health were worth $2,185,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its position in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of CVS Health during the fourth quarter valued at approximately $26,000. Sankala Group LLC purchased a new stake in CVS Health in the fourth quarter worth $28,000. Global Trust Asset Management LLC lifted its stake in CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 300 shares during the period. Finally, Mcguire Capital Advisors Inc. bought a new stake in CVS Health in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Analysts and market commentary pointed to improving execution, stronger payer margins, and a modest lift in CVS’s fair value estimate, suggesting Wall Street sees more upside in the stock. CVS Health (CVS) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
• Positive Sentiment: Options activity was unusually strong, with traders buying far more call options than normal, which can signal expectations for continued upside.
• Positive Sentiment: CVS’s new nationwide pet-prescription service has generated widespread coverage and could support pharmacy traffic and customer engagement. CVS is making it easier for pet owners with a new perk
• Neutral Sentiment: Brokerage coverage remains constructive, with CVS receiving a consensus “Moderate Buy” rating and another recent upgrade to Buy, reinforcing a generally favorable analyst stance. CVS Health Corporation (NYSE:CVS) Receives Consensus Rating of “Moderate Buy” from Brokerages
• Neutral Sentiment: Several articles highlighted CVS’s community-health investments in Massachusetts, but these are more reputational than immediately material to earnings. CVS Health Helping to Strengthen Communities Across Massachusetts
• Negative Sentiment: Henry Ford Health filed a lawsuit against CVS alleging a 340B pricing scheme, which could create legal and reputational risk if the claims gain traction. Henry Ford Health sues CVS, alleges 340B pricing scheme

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last three months. Corporate insiders own 0.85% of the company’s stock.

CVS Health Trading Down 1.1%

Shares of NYSE CVS opened at $106.86 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $110.68. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a 50-day moving average of $99.98 and a 200 day moving average of $85.97. The stock has a market cap of $136.35 billion, a P/E ratio of 47.08, a price-to-earnings-growth ratio of 1.06 and a beta of 0.61.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter last year, the firm earned $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. CVS Health’s payout ratio is presently 117.18%.

Analyst Upgrades and Downgrades

CVS has been the subject of several research reports. DA Davidson upped their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Weiss Ratings upgraded shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. JPMorgan Chase & Co. increased their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Truist Financial lifted their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Finally, Cantor Fitzgerald upped their target price on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $105.38.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.